LICENSE: This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.


9702341
22136
J Neural Transm (Vienna)
J Neural Transm (Vienna)
Journal of neural transmission (Vienna, Austria : 1996)
0300-9564
1435-1463

28770390
5654670
10.1007/s00702-017-1773-0
NIHMS897478
Article
Genome-wide Significant, Replicated and Functional Risk Variants for Alzheimer’s disease
Guo Xiaoyun 12*
Qiu Wenying 3#
Garcia-Milian Rolando 4
Lin Xiandong 5
Zhang Yong 6
Cao Yuping 7
Tan Yunlong 8
Wang Zhiren 8
Shi Jing 8
Wang Jijun 1
Liu Dengtang 1
Song Lisheng 1
Xu Yifeng 1
Wang Xiaoping 9
Liu Na 10
Sun Tao 11
Zheng Jianming 11
Luo Justine 2
Zhang Huihao 12
Xu Jianying 13
Kang Longli 14
Ma Chao 3
Wang Kesheng 15
Luo Xingguang 28*
1 Shanghai Mental Health Center, Shanghai 200030, China
2 Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
3 Department of Human Anatomy, Histology and Embryology, Institute of Basic Medical Sciences, Neuroscience Center, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100005, China
4 Curriculum &amp; Research Support Department, Cushing/Whitney Medical Library, Yale University School of Medicine, New Haven, CT 06510, USA
5 Department of Pathology, Fujian Provincial Cancer Hospital, the Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, China
6 Tianjin Mental Health Center, Tianjin 300222, China
7 Department of Psychiatry, Second Xiangya Hospital, Central South University, Changsha 410012, China
8 Biological Psychiatry Research Center, Beijing Huilongguan Hospital, Beijing 100096, China
9 Department of Neurology, Shanghai Tongren Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
10 Nanjing Brain Hospital, Nanjing Medical University, Nanjing 210029, China
11 Huashan Hospital, Fudan University School of Medicine, Shanghai 200040, China
12 The First Affiliated Hospital, Fujian Medical University, Fuzhou 350001, China
13 Zhuhai Municipal Maternal and Children’s Health Hospital, Zhuhai, Guangdong 519000, China
14 Key Laboratory for Molecular Genetic Mechanisms and Intervention Research on High Altitude Diseases of Tibet Autonomous Region, Xizang Minzu University School of Medicine, Xiangyang, Shaanxi 712082, China
15 Department of Biostatistics and Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN 37614, USA
* Correspondence: Xiaoyun.Guo@yale.edu (X.G.); Xingguang.Luo@yale.edu (X.L.); Tel.: +86-21-64387250
# These authors contribute equally

3 8 2017
02 8 2017
11 2017
01 11 2018
124 11 14551471
This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.
Genome-wide association studies (GWASs) have reported numerous associations between risk variants and Alzheimer’s disease (AD). However, these associations do not necessarily indicate a causal relationship. If the risk variants can be demonstrated to be biologically functional, the possibility of a causal relationship would be increased. In this article, we reviewed all of the published GWASs to extract the genome-wide significant (p&lt;5×10−8) and replicated associations between risk variants and AD or AD-biomarkers. The regulatory effects of these risk variants on the expression of a novel class of non-coding RNAs (piRNAs) and protein-coding RNAs (mRNAs), the alteration of proteins caused by these variants, the associations between AD and these variants in our own sample, the expression of piRNAs, mRNAs and proteins in human brains targeted by these variants, the expression correlations between the risk genes and APOE, the pathways and networks that the risk genes belonged to, and the possible long non-coding RNAs (LncRNAs) that might regulate the risk genes were analyzed, to investigate the potential biological functions of the risk variants and explore the potential mechanisms underlying the SNP-AD associations. We found replicated and significant associations for AD or AD-biomarkers, surprisingly, only at 17 SNPs located in 11 genes/snRNAs/LncRNAs in eight genomic regions. Most of these 17 SNPs enriched some AD-related pathways or networks, and were potentially functional in regulating piRNAs and mRNAs; some SNPs were associated with AD in our sample, and some SNPs altered protein structures. Most of the protein-coding genes regulated by the risk SNPs were expressed in human brain and correlated with APOE expression. We conclude that these variants were most robust risk markers for AD, and their contributions to AD risk was likely to be causal. As expected, APOE and the lipoprotein metabolism pathway possess the highest weight among these contributions.

Alzheimer’s disease
GWAS
genome-wide significant
replicated
risk variant
gene expression
APOE

1. Introduction

Alzheimer’s disease (AD) is the most common cause of dementia. It affects several millions of people worldwide. It is a primary neurodegenerative cerebral disease in the elderly, characterized by two major histopathologic changes in the brain, i.e., extracellular amyloid plaques that are composed of Aβ40 and Aβ42 and intracellular neurofibrillary tangles (NFT) that are composed of hyperphosphorylated protein Tau (Masters et al. 1985). The core cerebrospinal fluid (CSF) biomarkers for the diagnosis of AD include Aβ42 (amyloid-42 peptide), T-tau (total tau), and P-tau (phosphorylated tau) (Anoop et al. 2010).

From 2007 till July, 2017, 1055 genome-wide association studies (GWASs) and whole genome/exome sequencing studies of AD or AD-biomarkers have been published. However, the vast majority of these studies produced results that were not significant at genome-wide level and/or were not replicated by any other study, and thus might confuse or even mislead the readers. Although some studies reported “replicable” findings at gene level (i.e., different risk markers from the same gene), the replicable findings at individual marker level (i.e., same risk markers) were not common. Here, we only followed up the latter, which we believe can really be called “replicated” and more conservative, robust and reliable than the “gene-level” findings.

In this article, we reviewed all of these published studies, and extracted the most robust, i.e., both genome-wide significant (p&lt;5×10−8) and replicated, associations between risk SNPs and AD or AD-biomarkers. These associations themselves do not necessarily indicate a cause-effect relationship. However, if we can demonstrate that the risk SNPs are biologically functional, these associations are more likely to be causal ones. Thus, in this study, a series of functional analyses were conducted based on the pathway illustrated in Figure 1.

2. Summary of Materials and Methods (much detailed in the Supplementary Materials)

All associations between SNPs and AD/AD-biomarkers screened from the published literatures that are genome-wide significant (p&lt;5×10−8) and replicated across at least two independent studies are summarized in Table 1. These risk SNPs were genotyped in our own small cohort (6 AD and 6 controls) to replicate the SNP-AD association (Qiu et al. 2017), which was approved by the ethics committee of The Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences.

To explore the potential biological functions of these risk SNPs, we predicted their various functions using a series of bioinformatics analyses, and examined the potential regulatory effects of these SNPs on RNA expression using real molecular experiment, including the expression of the protein-coding mRNAs and the largest class of non-coding RNAs, i.e., piRNAs. The whole set of analyses was based on a regulation pathway illustrated in Figure 1.

For the mRNA expression, the genes that these risk SNPs are located were studied and the cis-regulatory effects of these SNPs on the mRNAs in human brains of a European cohort (n=134) were examined. For the piRNA expression, the transcriptome-wide piRNAs in human brains of our small Chinese cohort (6 AD and 6 controls; see above) were studied (Qiu et al. 2017) and the trans-regulatory effects of these SNPs on the piRNAs were examined. Furthermore, the expression of mRNAs and proteins encoding by these risk genes were examined in multiple brain regions in multiple independent European and American cohorts, the correlations between their mRNA expression and the APOE expression in brain were tested, and the most possible phenotype that these risk genes can predict for was explored using pathway/network analysis. Finally, the long non-coding RNAs (LncRNAs) proximate to these risk genes were explored. Integrating multiple independent pieces of positive evidence from these analyses would increase the possibility that the SNP-AD relationships are causal and suggest the potential mechanisms underlying these SNP-AD associations.

3. Results

3.1. Genome-wide Significant and Replicated Associations between SNPs and AD/AD-biomarkers

Although 10,393 candidate gene studies and 1055 GWASs on AD/AD-biomarkers have been published from 2007 till July, 2017, surprisingly, we could only extract the associations of 17 variants located in 11 genes/snRNAs/LncRNAs in eight loci from 28 studies that were genome-wide significant (1.0×10−295≤p≤9.0×10−9) and replicated across at least two independent studies (not only two independent samples in the same study) at single-point level. These eight loci include APOE cluster (NECTIN2-TOMM40-APOE-APOC1) (Abraham et al. 2008; Logue et al. 2011; Naj et al. 2010; Antunez et al. 2011; Feulner et al. 2010; Kim et al. 2011; Harold et al. 2009; Lambert et al. 2009; Nelson et al. 2014; Heinzen et al. 2010; Seshadri et al. 2010; Perez-Palma et al. 2014; Shen et al. 2010; Meda et al. 2012; Ramirez et al. 2014; Ramanan et al. 2014; Melville et al. 2012; Kamboh et al. 2012b; Li et al. 2008; Webster et al. 2008; Coon et al. 2007; Kamboh et al. 2012a), APOJ (Lambert et al. 2009; Jun et al. 2016; Lambert et al. 2013), SORL1 (Miyashita et al. 2013; Lambert et al. 2013; Jun et al. 2016), SLC24A4 (Jun et al. 2016; Lambert et al. 2013), CR1 (Lambert et al. 2013; Lambert et al. 2009), CD33 (Naj et al. 2011; Lambert et al. 2013), LOC105373605 (Kamboh et al. 2012b; Naj et al. 2011; Lambert et al. 2013; Jun et al. 2016; Hollingworth et al. 2011; Antunez et al. 2011; Hu et al. 2011) and RNU6-560P (Lambert et al. 2013; Jun et al. 2016; Harold et al. 2009) (Table 1), which is highly consistent with the gene list presented in the largest GWAS meta-analysis (Lambert et al. 2013). Among them, the associations between AD and variants (rs6859, rs157580, rs2075650, rs429358 and rs4420638) within APOE cluster are most robust. The associations between AD and rs6859 and rs157580 were replicated across three GWASs (8×10−89≤p≤6×10−14) (Abraham et al. 2008; Logue et al. 2011; Naj et al. 2010; Antunez et al. 2011; Feulner et al. 2010; Kim et al. 2011); the associations between either AD or age-of-onset of AD and rs4420638 were replicated across five GWASs (8×10−149≤p≤1×10−12) (Kamboh et al. 2012b; Coon et al. 2007; Li et al. 2008; Kamboh et al. 2012a; Webster et al. 2008); the associations between AD and rs2075650 were replicated across nine GWASs (1×10−295≤p≤3×10−11) (Harold et al. 2009; Lambert et al. 2009; Nelson et al. 2014; Heinzen et al. 2010; Seshadri et al. 2010; Perez-Palma et al. 2014; Naj et al. 2010; Kim et al. 2011; Shen et al. 2010); and the associations between AD or AD biomarkers (Aβ42, t-tau, p-tau181p, hippocampal, amygdalar or total cerebral volume) and rs429358+rs7412 (ε2/ε3/ε4) were replicated across eight GWASs (2×10−33≤p≤4×10−9) (Meda et al. 2012; Kim et al. 2011; Ramirez et al. 2014; Ramanan et al. 2014; Melville et al. 2012; Shen et al. 2010). Some of these associations have been validated by previous functional studies. Basically, other surrounding markers that might be in linkage disequilibrium with these 17 SNPs have not been reported to be genome-wide significant, replicated across studies or biologically functional (data not shown). Finally, more other phenotypes associated with these genes and the molecular functions of these genes are presented in Supplementary Table S1.

3.2. Bioinformatics Analysis

Among the 17 risk SNPs in Table 1, the only nonsynonymous variant is rs429358+rs7412 (ε2/ε3/ε4; Cys/Arg). It alters the APOE protein structure and has been demonstrated to be pathogenic, playing clinically significant roles in the development of AD. It is located at an 880bp CpG island of APOE, may alter the methylation status of this CpG island, and therefore affect the expression of APOE. One SNP at APOE cluster and one CD33 SNP at the transcription factor binding sites (TFBS) may affect the local DNA conformation and thereby influence the binding of transcription factors. Three SNPs located at the open chromatin regions are often associated with regulatory factor binding. Two SNPs may affect miRNA binding site activity, and therefore may regulate protein translation. Two SNPs are located in LncRNAs that might regulate the gene expression.

3.3. The Risk Variants May Regulate the Expression of Risk Genes in Human Brains

Cis-eQTL analysis showed that most SNPs had nominal cis-acting regulatory effects on mRNA expression (p&lt;0.05). The effect of rs6656401 on CR1 in HIPP (p=2.7×10−5) and WHMT (p=6.5×10−7), and the effects of rs2279590 and rs9331896 on APOJ in TCTX (p=1.3×10−4 and 4.5×10−4, respectively) and WHMT (p=1.4×10−4 and 1.5×10−4, respectively) remained significant after Bonferroni correction. (Table 2)

3.4. The Risk Variants May Regulate the Expression of piRNAs in brains

We found difference in genotype frequency of rs2075650 at APOE cluster (A/G genotype frequency: 0.714 vs. 0.111; p=0.029) and allele frequency (G allele frequency: 0.357 vs. 0.056; p=0.055) between AD cases and controls in our small cohort. The association between this marker and AD or AD-biomarkers has been reported to be the most robust one in literatures. It has been reported to be extremely significant (with lowest p values) and has been replicated across nine (the highest number) independent GWASs (Table 1). Our small cohort had 35% of power (calculated by an R program pwr.chisq.test) to detect this association based on the most significant finding reported previously (Seshadri et al. 2010).

eQTL analysis showed that some risk SNPs had transcriptome-wide significant (p&lt;5.3×10−6) regulatory effects on piRNAs (Table 3), including rs10792832 and rs3851179 at RNU6-560P and ε2/ε3/ε4 at APOE (9.4×10−8≤p≤4.7×10−6). (Table 3)

3.5. mRNA/Protein Expression of Risk Genes in Human Brain

Except for CR1 and CD33, other seven protein-coding genes, including APOJ, SORL1, SLC24A4, NECTIN2, TOMM40, APOE and APOC1, had significant mRNA expression (36&lt; normalized intensity &lt;9088 or 1&lt;RPKM&lt;779) in 26 human brain regions in the three independent cohorts (Table 4). Specifically, in the first UK European cohort, all of these seven protein-coding genes were expressed in the ten brain regions including CRTX, FCTX, HIPP, MEDU, OCTX, PUTM, SNIG, TCTX, THAL, and WHMT (all log2(normalized intensity) &gt; 5.17), except for the low expression of SLC24A4 in CRTX. In the American cohort, all seven genes were expressed in CTX, FCTX, ACTX, HPTH, HIPP, SNIG, NACC, CDNL, PUTM, AMYG, CRHM, CRBL and/or PITT. Among these seven genes, APOE (201.40≤RPKM≤778.30) and APOJ (48.90≤RPKM≤602.00) were expressed in highest density across all 13 brain regions, except for low expression of APOE in PITT. In the second UK European cohort, all seven genes were expressed in at least one of the 17 brain regions, including AMYG, CDNL, CRBL, CRPD, CCTX, DRGL, FTBR, HPTH, MEDU, OCTX, PITT, PONS, PFCX, TCTX, THAL, WHOL and PINL. Among these seven genes, APOE (102.58≤ normalized intensity ≤1875.35) and APOJ (856.65≤ normalized intensity ≤9087.92) were expressed in highest density across all 17 brain regions. Finally, in the Germany cohort, proteomic analysis showed that APOJ, TOMM40, APOE and APOC1 had significant protein expression in WHOL, FCTX or CRTX. Among these four genes, APOE (40ppm≤concentration≤267ppm) and APOJ (40≤ concentration≤291) were expressed in highest density across all three brain regions.

3.6. The Expression of Eight Protein-Coding Genes Was Correlated with APOE Expression

The mRNA expression of all eight risk genes in brain was significantly correlated with APOE expression in at least one of the ten brain regions in the UK European cohort (0.29≤|r|≤0.81; 2.9×10−32≤p≤6.2×10−4), and APOJ, SORL1, APOE and APOC1 belong to the same lipoprotein metabolism pathway (www.reactome.org). Except for the negative correlations (r&lt;0) between SORL1 and APOE in OCTX, FCTX and TCTX and between SLC24A4 and APOE in OCTX, all others were positive (r&gt;0) (Table 5)

3.7. Gene network and pathway analysis

Overrepresentation analysis using IPA identified biological pathways containing a statistically significant excess of these genes. The top 5 canonical pathways found to be overrepresented in these genes using IPA are shown in Table 6. Two canonical pathways related to the retinoid X receptor were the most significant enriched pathways: LXR/RXR Activation (p=1.50×10−5) and FXR/RXR Activation pathways (p=1.72×10−5). These were followed by Atherosclerosis Signaling (p=1.74×10−5), IL-12 Signaling and Production in Macrophages (p=2.64×10−5), and Production of Nitric Oxide and Reactive Oxygen Species in Macrophages (p=6.07×10−5) pathaways. Late-onset AD (p=1.75×10−10), efflux of phospholipid (p=1.92×10−7), AD (p=2.20×10−7), familial amyloidosis (p=4.48×10−7), lattice corneal dystrophy type I (p=4.84×10−7) were the top enriched diseases and functions. Only the network for Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry was significantly enriched (Score=23). IPA knowledge base significantly associated this network to both late-onset AD (p=1.75×10−10), and AD (p=2.20×10−7) as shown in Figure 2.

Current network and pathway analysis is limited by the state of current knowledge about gene interactions and functions in the biomedical literature. Thus, well studied genes have more complete, validated interaction and functional data in contrast to less studied ones. In this regard, these results represent our findings with respect to the current state of knowledge.

3.8. The LncRNAs Related to the Replicated Risk Genes

The LncRNAs proximate to each gene are listed in Table 7. One sense LncRNA 2.9 kb to SLC24A4 is a large intergenic non-coding RNA (LincRNA), with a length of 15 kb; three others overlapping with or close to SORL1 and CD33 are antisense LncRNAs, with lengths of 12 kb to 31 kb. The results presented above are also illustrated in Figure 1.

4. Discussion

More than 10,000 genetic studies of AD have been published so far, and over 560 genes have been “associated” with AD risk, which might confuse the readers and some might mislead them due to the non-replicability issue. Our analysis first explicitly showed that, after stringent screening, only 17 SNPs in eight loci were robustly associated with AD; that is, these SNPs were biologically functional and potentially causal, and their associations with AD were genome-wide significant and replicated across independent studies. Most of these eight loci enriched some AD-related pathways or networks. We believe these SNPs/loci should have the highest possibility of contribution to AD risk. APOE and the lipoprotein metabolism pathway possess the highest weight among this contribution, as expected though. These risk SNPs/loci contribute to AD risk probably via common or distinct mechanisms. These mechanisms may be related to the direct or indirect regulatory functions of the risk variants. We illustrate possible mechanisms underlying these SNP-AD associations in Figure 1.

The cis-eQTL and bioinformatics analyses provided evidence to support that these replicated risk SNPs might be biologically functional in regulating piRNAs and mRNAs, altering protein structures, and influencing the transcription, expression and splicing of the risk genes. Many piRNAs, mRNAs and proteins targeted by these variants were expressed in human brains. This evidence increased the possibility that these risk SNPs might play functional roles in AD development.

As expected, association between APOE and AD has been intensively reported and is most robust. APOE is highly abundant in human brains. It may be directly involved in AD pathology or indirectly through a β-amyloid (Aβ) or tau pathway (Puglielli et al. 2003; Namba et al. 1991; Lilius et al. 1999). Six other protein-coding risk genes, including APOJ, SORL1, SLC24A4, NECTIN2, TOMM40 and APOC1, were significantly expressed in multiple human brain regions too. They were all correlated with APOE in expression. NECTIN2, TOMM40 and APOC1 are closely located within the same genomic cluster as APOE. APOJ, SORL1 and APOC1 belong to the same lipoprotein metabolism pathway (www.reactome.org) as APOE too. This pathway is critical in redistributing cholesterol and phospholipids in brains, responsible for the apoE4-associated neuropathology including the formation of neurotoxic fragments that have been demonstrated to be involved in the development of AD (Mahley 2016; Jones et al. 2010). APOE and APOJ expression in brains is the most abundant among all risk genes for AD. Apparently, APOE and the lipoprotein metabolism pathway possess the highest weight in contribution to the AD risk. Moreover, SLC24A4 is involved in neural development (Larsson et al. 2011). RIN3 next to SLC24A4 interacts with BIN1 in the early endocytic pathway (Kajiho et al. 2003), and BIN1 is another well-known risk gene for AD, which is probably the alternative non-APOE pathway via which SLC24A4 is implicated in AD (Tan et al. 2013).

The protein-coding risk gene CD33 was expressed a little bit lower than the threshold in brains in our four independent brain tissue cohorts (data not shown). However, this low expression was significantly correlated with APOE expression in SNIG and TCTX in our cohorts, and literatures have also reported low expression of CD33 around the threshold mainly in microglial cells (Jiang et al. 2014), which suggested it might still be able to play a direct functional role in AD too. CD33 can inhibit the uptake and clearance of Aβ42 in microglial cells and CD33 inactivation can mitigates Aβ pathology (Griciuc et al. 2013). CD33 was associated with accumulation of neuritic amyloid pathology and fibrillar amyloid, and increased numbers of activated human microglia (Bradshaw et al. 2013).

The protein-coding risk gene CR1 (i.e., CD35) was expressed much lower than the threshold in brains in our four independent brain cohorts (data not shown), consistent with previous reports (Fonseca et al. 2016). However, this very low expression was also significantly correlated with APOE expression in multiple brain regions in our cohorts. Some studies have also reported low expression of CR1 in some brain regions (Chibnik et al. 2011; Bralten et al. 2011), and CR1 interacted with APOE and participated in the clearance of β amyloid (Aβ) peptide. Aβ is the principal constituent of amyloid plaques that is one of the major brain lesions of individuals with AD (Thambisetty et al. 2013; Lambert et al. 2009; Biffi et al. 2012).

Additional functional pathway and network analysis with IPA suggested that more other pathways that these risk genes belong to might also be involved in AD. The top most significant canonical pathways resulting from the enrichment analysis were related to the retinoid X receptors (RXRs). Recent studies have pointed to a role of liver X receptor, a RXR binding partner, in the AD pathophysiology (Sandoval-Hernandez et al. 2015). The third most significant enriched canonical pathway was Atherosclerosis signaling. The association between cerebrovascular atherosclerosis and AD has been examined in many cross-sectional studies (Kim et al. 2016). Both Atherosclerosis and AD involve inflammation and macrophage infiltration (Lathe et al. 2014). Subsequently, two canonical pathways indicative of macrophage activation [production of IL-12 and nitric oxide and reactive oxygen species (NOROS)] were among the top 5 significantly enriched pathways. The NOROS pathway was listed as top 1 by a previous report (Li et al. 2015). Finally, if analyzed using MetaCore, the top 4 significantly enriched canonical pathways were all “immune response” pathways (data not shown), consistent with a previous report (Jones et al. 2010).

Recent evidence suggests that piRNAs are abundant in the brain (Mani and Juliano 2013; Rajasethupathy et al. 2012; Lee et al. 2011; Sharma et al. 2001; Perrat et al. 2013; Yan et al. 2011; Ghildiyal et al. 2008; Dharap et al. 2011; Peng and Lin 2013; Zuo et al. 2016b; Qiu et al. 2017). piRNAs may regulate the mRNAs and translation of the proximate risk genes (Grivna et al. 2006) or interact with neurotransmitters in brains (Ross et al. 2014; Rajasethupathy et al. 2012), and thus may play roles in brain disorders. Our transcriptome-wide eQTL screening demonstrated that the risk SNPs, especially in non-coding loci, might have trans-regulatory effects on piRNAs, which may suggest a novel mechanism underlying the SNP-disease associations.

Finally, five risk variants are located within or close to either an antisense LncRNA (i.e., LOC105373605) or a snRNA that does not encode any protein. These LncRNA and snRNA are proximate to BIN1 and PICALM, respectively. BIN1 and PICALM are expressed in human brains and have widely been associated with AD by numerous studies (Wang et al. 2016; Holler et al. 2014). The antisense LncRNA and snRNA might use diverse transcriptional and post-transcriptional mechanisms (Faghihi and Wahlestedt 2009; Villegas and Zaphiropoulos 2015; Zuo et al. 2016a) to regulate BIN1 and PICALM, respectively, to play roles in AD. PICALM and BIN1 were modifiers of Aβ toxicity and they could promote APP internalization, endocytic trafficking, and Aβ generation in neurons in vitro (Xiao et al. 2012; Treusch et al. 2011). Furthermore, several risk genes, e.g., SORL1, SLC24A4 and CD33, overlap with or are close to LncRNAs in genomic location, also suggesting the role of LncRNAs in AD. These hypotheses regarding LncRNAs and snRNAs should be tested in the future.

Supplementary Material

sup Supplementary Table S1. Biological functions of the risk genes/RNAs

This work was supported in part by National Institute on Drug Abuse (NIDA) grant K01 DA029643, National Institute on Alcohol Abuse and Alcoholism (NIAAA) grants R21 AA021380, R21 AA020319 and R21 AA023237, Chinese National Science Foundation (81201057), Shanghai Clinical Center for Psychiatric Disease, and Shanghai Municipal Commission Award (20124109).

Figure 1 Illustration for the pathways underlying SNP-AD association

[Solid lines: Directly evidenced by our study; Dash lines: Indirectly evidenced by literatures. &amp;#x02776; LncRNA expression is regulated by the SNPs (by eQTL analysis); &amp;#x02777; LncRNAs regulate the expression of the nearest protein-coding genes by sequence complementarity; &amp;#x02778; mRNA expression of the risk genes is correlated to APOE mRNA expression (by correlation analysis); &amp;#x02779; mRNA of APOE encodes APOE protein, and both mRNA and protein of APOE are expressed in brain and related to AD; &amp;#x0277A; RNAs/proteins expressed in brain are assumed to have potential brain functions; &amp;#x0277B; many brain functions are assumed to be related to the development of AD; &amp;#x0277C; piRNA expression is regulated by the risk SNPs (by transcriptome-wide eQTL analysis); &amp;#x0277D; piRNAs regulate the expression of the nearest protein-coding genes by sequence complementarity; &amp;#x0277E; mRNAs encode proteins; &amp;#x0277F; proteins are expressed in brains (by mass spectrometry-based proteomics microarray analyses); &amp;#x024EB; mRNA expression is regulated by the risk SNPs (by cis-eQTL analysis and bioinformatic analysis); &amp;#x024EC; protein structures are altered by SNPs (by bioinformatics analysis); &amp;#x024ED; mRNA expression of risk genes is detected in brains (by RNA-Seq or RNA microarray analyses); &amp;#x024EE; SNPs are associated with AD (by our study or published GWASs); &amp;#x024EF; piRNAs are detected in brains (by microarray)]

Figure 2 The significantly enriched network Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry

[This figure was generated from a Core Analysis in IPA for the risk genes (green-colored) and their relationship to AD (red-colored)]

Table 1 Replicated associations between genes and Alzheimer’s disease

SNP	Location(GRCh38)	Gene (Alias) [Class]	Functional class	p-value	Ref.	p-value	Ref.	p-value	Ref.	
rs6656401	chr1:207518704	CR1 (CD35)	Intron; chromatin	6×10−24	[1]	4×10−9	[2]			
rs7561528	chr2:127132061	LOC105373605 [LncRNA]	Intron	6×10−11	[3]	4×10−14	[4]			
rs6733839	chr2:127135234	LOC105373605 [LncRNA]	Intron; chromatin	7×10−44	[1]	1×10−9 *	[5]			
rs744373	chr2:127137039	LOC105373605 [LncRNA]	3′	3×10−14	[6]	2×10−9	[7]	1×10−10	[8]	
rs2279590	chr8:27598736	APOJ (CLU)	Exon; chromatin	9×10−9	[2]	2×10−6 **	[5]			
rs9331896	chr8:27610169	APOJ (CLU)	Intron; miRNA	3×10−25	[1]	3×10−9 **	[5]			
rs11218343	chr11:121564878	SORL1 (LRP9)	Intron	2×10−9	[9]	1×10−14	[1]	9×10−6 **	[5]	
rs10792832	chr11:86156833	RNU6−560P [snRNA]	3′	9×10−26	[1]	4×10−6 *	[5]			
rs3851179	chr11:86157598	RNU6-560P [snRNA]	3′	1×10−9	[10]	2×10−6 **	[5]			
rs10498633	chr14:92460608	SLC24A4 (SHEP6)	Intron	6×10−9	[1]	4×10−7 **	[5]			
rs6859	chr19:44878777	NECTIN2-TOMM40-APOE-APOC1	Exon of NECTIN2;miRNA	6×10−14	[11]	5×10−7	[12]	1×10−7	[13]	
rs157580	chr19:44892009	NECTIN2-TOMM40-APOE-APOC1	Intron of TOMM40;TFBS	8×10−89	[7]	1×10−40	[14]	&lt;1×10−6 #	[15]	
rs2075650	chr19:44892362	NECTIN2-TOMM40-APOE-APOC1	Intron of TOMM40	2×10−157	[10]	2×10−16	[2]	4×10−13	[16]	
		(CD112-TOMM40-APOE-APOC1)		3×10−11	[17]	1×10−295	[18]	9×10−116	[19]	
		(APOE cluster)		5×10−36	[13]	&lt;10−6 Δ,ΔΔ	[15]	&lt;10−6¶	[20]	
rs429358	chr19:44908684	NECTIN2-TOMM40-APOE-APOC1	Exon of APOE; 3D;	7×10−16	[21]	4×10−9	[21]	&lt;10−6 #,###,Δ,ΔΔ	[15]	
 +rs7412			Pathogenic; CpG	4×10−17 #	[22]	5×10−14 #	[23]	2×10−33¶	[24]	
(ε2/ε3/ε4)				1×10−7 ¶	[24]	&lt;10−6¶	[20]			
rs4420638	chr19:44919689	NECTIN2-TOMM40-APOE-APOC1	3’ to APOC1	8×10−149	[3]	2×10−44	[25]	1×10−39	[26]	
				1×10−39	[27]	1×10−12 ø	[28]			
rs3865444	chr19:51224706	CD33	Exon of CD33; TFBS	2×10−9	[4]	3×10−6	[1]			
All target traits are Alzheimer’s disease, except for the following.

* in APOE^ε4 carriers (*) or non-APOE^ε4 carriers (**);

ø age of onset of AD;

#/Δ associated with Aβ42 (amyloid-42 peptide) (#), t-tau (total cerebrospinal fluid tau) (##), p-tau181p (tau phosphorylated at threonine 181) (###), t-tau/Aβ42 (Δ), p-tau181p/Aβ42 (ΔΔ);

¶ hippocampal, amygdalar or total cerebral volume.

LncRNA, long non-coding RNA; snRNA, small nuclear RNA. TFBS, these SNPs are located in the transcription factor binding sites; chromatin, this SNP is located in an open chromatin region; miRNA, these SNPs may affect miRNA binding site activity, which may regulate protein translation; pathogenic, this SNP is clinically pathogenic; 3D, this SNP alters the protein structure; CpG, this SNP is located at an 880bp CpG island.

Table 2 cis-acting expression of quantitative locus (cis-eQTL) analysis on the risk markers in human brains of a UK European cohort (n=134)

SNPs	Target	FCTX	TCTX	OCTX	PUTM	THAL	HIPP	SNIG	WHMT	
rs6656401	CR1	0.014	4.0×10−3		0.049	0.013	2.7×10−5 *		6.5×10−7 *	
rs2279590	APOJ	3.9×10−4	1.3×10−4 *	7.8×10−4			1.5×10−3	0.011	1.4×10−4 *	
rs9331896	APOJ	1.2×10−3	4.5×10−4	7.7×10−4			6.9×10−4	0.029	1.5×10−4 *	
rs6859	TOMM40	5.0×10−3								
rs157580	NECTIN2	0.036		8.1×10−4						
rs2075650	NECTIN2	0.034								
rs2075650	TOMM40	0.047								
rs429358	NECTIN2	0.015								
rs429358	APOC1						0.050			
rs4420638	APOC1		0.017							
rs3865444	CD33		0.017							
The SNP list refers to Table 1. Brain regions: frontal cortex (FCTX), temporal cortex (TCTX), occipital cortex (specifically primary visual cortex, OCTX), putamen (PUTM), thalamus (THAL), hippocampus (HIPP), substantia nigra (SNIG), and intralobular white matter (WHMT).

* The effects remaining significant after Bonferroni correction are bold, i.e., p&lt;α=2.0×10−4=0.05/(10 brain tissues × 25 regulations).

Table 3 The piRNAs significantly correlated with risk SNPs for AD

piRNA	location	RNU6-560P	APOE	
		
rs10792832	rs3851179	(ε2/ε3/ε4)	
DQ571511	SNORD49A	2.8×10−7	2.8×10−7		
DQ570728	SNORD63	4.0×10−6	4.0×10−6		
DQ596993	SNORD110	4.7×10−6	4.7×10−6		
DQ581176	Close to DLG5			4.1×10−7	
DQ589995	LRRC37A4P			3.3×10−6	
DQ574832	Close to BUB1			5.1×10−6	
DQ574527	FAM95B1			9.4×10−8	
DQ577188	GOLGA6L9			4.3×10−6	
DQ571900	LINC00837			3.0×10−6	
α=5.3×10−6

Table 4 The mRNA and protein expression of risk genes in human brains in four cohorts

	WHOL	CTX	PFCX	FCTX	TCTX	ACTX	OCTX	CRTX	HPTH	HIPP	SNIG	NACC	CDNL	PUTM	MEDU	AMYG	CRHM	CRBL	PITT	THAL	CRPD	DRGL	FTBR	PONS	PINL	WHMT	
mRNA expression in a UK European cohort (n=134) [log2-transformed normalized intensity values from Affymetrix Human ST 1.0 exon arrays]:	
APOJ				8.9	8.8		8.7	8.7		9.0	9.1			8.9	9.2					9.1						8.8	
SORL1				8.9	8.8		8.9	8.7		8.7	8.8			8.0	8.6					8.5						8.8	
SLC24A4				5.8	5.9		6.1	-		5.5	6.2			5.3	6.5					6.0						5.8	
NECTIN2				6.2	6.2		6.1	5.9		6.4	6.5			6.3	6.5					6.4						6.2	
TOMM40				6.3	6.3		6.3	6.4		6.2	6.3			6.3	6.3					6.2						6.4	
APOE				6.7	6.7		6.6	6.6		7.0	7.8			7.5	7.1					7.4						7.1	
APOC1				5.4	5.4		5.5	5.3		5.5	5.8			5.8	5.5					5.6						5.6	
mRNA expression in an American cohort (n=2712) [RPKM values from RNA-Seq]:	
APOJ		585.6		564.4		565.5			391.8	376.8	468.2	540.5	602.0	547.9		475.5	307.6	423.6	48.9								
SORL1		14.1		17.4		11.6			10.0	11.0	13.8	9.0	9.0	6.4		7.8	19.7	20.3	15.3								
SLC24A4		1.8		1.3		-			-	-	1.2	1.1	-	-		-	-	-	-								
NECTIN2		4.6		4.1		4.6			5.8	4.0	5.2	3.9	4.4	4.1		4.7	2.0	3.4	15.6								
TOMM40		11.0		10.7		8.3			9.3	7.4	8.0	7.4	7.4	7.5		6.4	12.5	12.5	10.0								
APOE		252.8		239.0		331.6			519.9	289.6	753.4	778.3	791.1	762.3		556.2	201.4	269.8	-								
APOC1		4.2		4.0		4.7			43.6	11.1	75.1	81.2	78.9	72.6		25.8	-	-	3.4								
mRNA expression in a UK European cohort (n=176; BioGPS) [normalized intensity values from Affymetrix microarray]:	
APOJ	5671.0		9087.9		2467.2	2637.9	3509.0		5470.7				3132.7		2342.2	6874.6		2878.1	729.9	3995.2	3565.2	1737.8	856.7	2452.2	8721.4		
SORL1	607.9		1144.0		288.1	355.1	523.7		472.8				131.8		415.3	510.0		320.9	420.1	219.1	509.9	-	83.9	198.9	848.6		
SLC24A4	45.5		43.7		47.9	49.5	48.2		47.2				50.9		48.7	45.5		47.9	48.2	48.7	48.3	48.4	47.6	48.4	46.8		
NECTIN2	-		-		-	34.2	-		-				-		-	-		-	32.2	-	-	-	-	-	63.0		
TOMM40	220.1		398.3		449.5	514.7	274.7		303.1				312.2		322.3	245.8		259.6	365.3	697.0	697.0	307.5	334.2	519.9	355.1		
APOE	1139.5		818.9		417.9	461.3	528.3		1769.5				990.9		438.2	1875.4		591.3	102.6	506.2	809.8	158.9	193.5	449.7	403.7		
APOC1	40.8		32.0		32.7	134.5	40.8		150.8				164.8		95.6	56.4		-	65.6	122.7	30.1	33.6	-	100.1	36.0		
protein expression in a Germany cohort (ProteomicsDB) [ppm values from mass spectrometry-based proteomics arrays]:	
APOJ	291			65				40																			
TOMM40	149			27				-																			
APOE	267			221				40																			
APOC1	-			10				19																			
The expression levels less than thresholds are not listed in this table [normalized intensity &lt; 36, i.e., log2(normalized intensity) &lt; 5.17 from microarray; RPKM &lt; 1 from RNA-Seq; or raw protein concentration value &lt; 10ppm from HPLC]. Brain regions: whole brain (WHOL), cortex (CTX), prefrontal cortex (PFCX), anterior cingulate cortex (ACTX), cerebellar cortex (CRTX), hypothalamus (HPTH), nucleus accumbens (NACC), caudate nucleus (CDNL), medulla (specifically inferior olivary nucleus, MEDU), amygdala (AMYG), cerebellar hemisphere (CRHM), pituitary (PITT), cerebellum peduncles (CRPD), dorsal root ganglion (DRGL), fetal brain (FTBR), pons (PONS), and pineal (PINL). Other abbreviations refer to Table 2.

Table 5 Significant expression correlation between APOE and other risk genes in human brain (n=134)

	CR1	APOJ	SORL1	SLC24A4	NECTIN2	TOMM40	APOC1	CD33	
r	p	r	p	r	p	r	p	r	p	r	p	r	p	r	p	
CRBL			.54	3.8×10−11			.30	5.2×10−4	.60	7.2×10−14							
FCTX					−.49	1.6×10−9			.44	1.1×10−7							
HIPP			.34	4.9×10−5					.47	8.2×10−9							
MEDU	.32	2.0×10−4	.51	4.7×10−10			.35	3.6×10−5	.42	8.2×10−7							
OCTX			.58	3.3×10−13	−.52	1.2×10−10	−.40	1.3×10−6	.63	4.0×10−16							
PUTM			.48	3.6×10−9			.37	1.2×10−5	.60	1.1×10−14	.31	2.2×10−4	.29	6.2×10−4			
SNIG	.44	2.1×10−7	.71	4.0×10−21			.73	2.2×10−23	.81	2.9×10−32			.70	1.2×10−20	.70	7.5×10−21	
TCTX	.47	9.5×10−9	.56	3.4×10−12	−.55	5.3×10−12			.64	1.0×10−16			.32	1.9×10−4	.33	1.3×10−4	
THAL	.39	2.7×10−6	.46	2.2×10−8			.61	5.3×10−15	.54	2.9×10−11			.49	3.1×10−9			
WHMT			.47	1.5×10−8			.39	2.9×10−6	.33	1.1×10−4							
The abbreviations of brain regions refer to Table 4. r, correlation coefficient; α=6.3×10−4=0.05/(10 brain tissues × 8 genes); any correlation with p&gt;α is not listed in this table.

Table 6 Enrichment analysis for the risk genes using IPA

Pathway/Phenotype/Network	p-value/score	
Ingenuity Canonical Pathways		
 LXR/RXR Activation	1.50×10−5	
 FXR/RXR Activation	1.72×10−5	
 Atherosclerosis Signaling	1.74×10−5	
 IL-12 Signaling and Production in Macrophages	2.64×10−5	
 Production of Nitric Oxide and Reactive Oxygen Species in Macrophages	6.07×10−5	
Diseases or Functions Annotation		
 late-onset Alzheimer’s disease	1.92×10−10	
 efflux of phospholipid	1.75×10−7	
 Alzheimer’s disease	2.20×10−7	
 familial amyloidosis	4.48×10−7	
 lattice corneal dystrophy type I	4.84×10−7	
Networks		
 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry	score: 23	

Table 7 The LncRNAs or snRNAs proximate to the replicated risk genes for AD

LncRNA name (NCBI Gene)	Alias	Length (nt)	Distance to risk gene	Category	
XR_948110.2	LOC105369536	13,932	Overlap with exons 1&amp;2 of SORL1	antisense LncRNA	
XP_016874140.1	LOC105369535	11,887	Covered by SORL1	antisense LncRNA	
XR_944153.1	LOC105370627	15,237	2,931bp to TSS of SLC24A4	sense LincRNA	
XR_001753982.1	LOC107985327	31,013	148bp to 3′ of CD33	antisense LncRNA	
XR_923311.2	LOC105373605	29,009	99bp to 3′ of BIN1	antisense LncRNA	
NC_000011.10	RNU6-560P	108	83,453bp to TSS of PICALM	snRNA	
Sense, LncRNAs are transcribed from the same genomic strand as the protein-coding mRNAs; Antisense, LncRNAs are transcribed from the antisense strand.

Conflict of Interest: The authors declare no conflict of interest.

Author Contributions

Conceived and designed the experiments: X.G. X.L.

Performed the experiments: X.L. X.G. R.G.M. W.Q. X.L. Y.T. Z.W. C.M. Y.Z. X.W. Y.Z. Y.C. J.S. J.W. D.L. L.S. Y.X. N.L. T.S. J.Z. J.L. H.Z. J.X. L.K.

Analyzed the data: X.G. X.L. C.R.L. K.W.

Contributed reagents/materials/analysis tools: X.L. R.G.M.

Wrote the manuscript: X.G. X.L. R.G.M.


Abraham R Moskvina V Sims R Hollingworth P Morgan A Georgieva L Dowzell K Cichon S Hillmer AM O’Donovan MC Williams J Owen MJ Kirov G 2008 A genome-wide association study for late-onset Alzheimer’s disease using DNA pooling BMC Med Genomics 1 44 10.1186/1755-8794-1-44 18823527
Anoop A Singh PK Jacob RS Maji SK 2010 CSF Biomarkers for Alzheimer’s Disease Diagnosis International journal of Alzheimer’s disease 2010 10.4061/2010/606802
Antunez C Boada M Gonzalez-Perez A Gayan J Ramirez-Lorca R Marin J Hernandez I Moreno-Rey C Moron FJ Lopez-Arrieta J Mauleon A Rosende-Roca M Noguera-Perea F Legaz-Garcia A Vivancos-Moreau L Velasco J Carrasco JM Alegret M Antequera-Torres M Manzanares S Romo A Blanca I Ruiz S Espinosa A Castano S Garcia B Martinez-Herrada B Vinyes G Lafuente A Becker JT Galan JJ Serrano-Rios M Vazquez E Tarraga L Saez ME Lopez OL Real LM Ruiz A Alzheimer’s Disease Neuroimaging I 2011 The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease Genome Med 3 5 33 10.1186/gm249 21627779
Biffi A Shulman JM Jagiella JM Cortellini L Ayres AM Schwab K Brown DL Silliman SL Selim M Worrall BB Meschia JF Slowik A De Jager PL Greenberg SM Schneider JA Bennett DA Rosand J 2012 Genetic variation at CR1 increases risk of cerebral amyloid angiopathy Neurology 78 5 334 341 10.1212/WNL.0b013e3182452b40 22262751
Bradshaw EM Chibnik LB Keenan BT Ottoboni L Raj T Tang A Rosenkrantz LL Imboywa S Lee M Von Korff A Morris MC Evans DA Johnson K Sperling RA Schneider JA Bennett DA De Jager PL Alzheimer Disease Neuroimaging I 2013 CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology Nature neuroscience 16 7 848 850 10.1038/nn.3435 23708142
Bralten J Franke B Arias-Vasquez A Heister A Brunner HG Fernandez G Rijpkema M 2011 CR1 genotype is associated with entorhinal cortex volume in young healthy adults Neurobiology of aging 32 11 2106e2107 2111 10.1016/j.neurobiolaging.2011.05.017
Chibnik LB Shulman JM Leurgans SE Schneider JA Wilson RS Tran D Aubin C Buchman AS Heward CB Myers AJ Hardy JA Huentelman MJ Corneveaux JJ Reiman EM Evans DA Bennett DA De Jager PL 2011 CR1 is associated with amyloid plaque burden and age-related cognitive decline Ann Neurol 69 3 560 569 10.1002/ana.22277 21391232
Coon KD Myers AJ Craig DW Webster JA Pearson JV Lince DH Zismann VL Beach TG Leung D Bryden L Halperin RF Marlowe L Kaleem M Walker DG Ravid R Heward CB Rogers J Papassotiropoulos A Reiman EM Hardy J Stephan DA 2007 A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease J Clin Psychiatry 68 4 613 618 17474819
Dharap A Nakka VP Vemuganti R 2011 Altered expression of PIWI RNA in the rat brain after transient focal ischemia Stroke 42 4 1105 1109 10.1161/STROKEAHA.110.598391 21311060
Faghihi MA Wahlestedt C 2009 Regulatory roles of natural antisense transcripts Nature reviews Molecular cell biology 10 9 637 643 10.1038/nrm2738 19638999
Feulner TM Laws SM Friedrich P Wagenpfeil S Wurst SH Riehle C Kuhn KA Krawczak M Schreiber S Nikolaus S Forstl H Kurz A Riemenschneider M 2010 Examination of the current top candidate genes for AD in a genome-wide association study Mol Psychiatry 15 7 756 766 10.1038/mp.2008.141 19125160
Fonseca MI Chu S Pierce AL Brubaker WD Hauhart RE Mastroeni D Clarke EV Rogers J Atkinson JP Tenner AJ 2016 Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function PLoS One 11 2 e0149792 10.1371/journal.pone.0149792 26914463
Ghildiyal M Seitz H Horwich MD Li C Du T Lee S Xu J Kittler EL Zapp ML Weng Z Zamore PD 2008 Endogenous siRNAs derived from transposons and mRNAs in Drosophila somatic cells Science 320 5879 1077 1081 10.1126/science.1157396 18403677
Griciuc A Serrano-Pozo A Parrado AR Lesinski AN Asselin CN Mullin K Hooli B Choi SH Hyman BT Tanzi RE 2013 Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta Neuron 78 4 631 643 10.1016/j.neuron.2013.04.014 23623698
Grivna ST Beyret E Wang Z Lin H 2006 A novel class of small RNAs in mouse spermatogenic cells Genes Dev 20 13 1709 1714 10.1101/gad.1434406 16766680
Harold D Abraham R Hollingworth P Sims R Gerrish A Hamshere ML Pahwa JS Moskvina V Dowzell K Williams A Jones N Thomas C Stretton A Morgan AR Lovestone S Powell J Proitsi P Lupton MK Brayne C Rubinsztein DC Gill M Lawlor B Lynch A Morgan K Brown KS Passmore PA Craig D McGuinness B Todd S Holmes C Mann D Smith AD Love S Kehoe PG Hardy J Mead S Fox N Rossor M Collinge J Maier W Jessen F Schurmann B van den Bussche H Heuser I Kornhuber J Wiltfang J Dichgans M Frolich L Hampel H Hull M Rujescu D Goate AM Kauwe JS Cruchaga C Nowotny P Morris JC Mayo K Sleegers K Bettens K Engelborghs S De Deyn PP Van Broeckhoven C Livingston G Bass NJ Gurling H McQuillin A Gwilliam R Deloukas P Al-Chalabi A Shaw CE Tsolaki M Singleton AB Guerreiro R Muhleisen TW Nothen MM Moebus S Jockel KH Klopp N Wichmann HE Carrasquillo MM Pankratz VS Younkin SG Holmans PA O’Donovan M Owen MJ Williams J 2009 Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease Nature genetics 41 10 1088 1093 19734902
Heinzen EL Need AC Hayden KM Chiba-Falek O Roses AD Strittmatter WJ Burke JR Hulette CM Welsh-Bohmer KA Goldstein DB 2010 Genome-wide scan of copy number variation in late-onset Alzheimer’s disease J Alzheimers Dis 19 1 69 77 10.3233/JAD-2010-1212 20061627
Holler CJ Davis PR Beckett TL Platt TL Webb RL Head E Murphy MP 2014 Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer’s disease brain and correlates with neurofibrillary tangle pathology J Alzheimers Dis 42 4 1221 1227 10.3233/JAD-132450 25024306
Hollingworth P Harold D Sims R Gerrish A Lambert JC Carrasquillo MM Abraham R Hamshere ML Pahwa JS Moskvina V Dowzell K Jones N Stretton A Thomas C Richards A Ivanov D Widdowson C Chapman J Lovestone S Powell J Proitsi P Lupton MK Brayne C Rubinsztein DC Gill M Lawlor B Lynch A Brown KS Passmore PA Craig D McGuinness B Todd S Holmes C Mann D Smith AD Beaumont H Warden D Wilcock G Love S Kehoe PG Hooper NM Vardy ER Hardy J Mead S Fox NC Rossor M Collinge J Maier W Jessen F Ruther E Schurmann B Heun R Kolsch H van den Bussche H Heuser I Kornhuber J Wiltfang J Dichgans M Frolich L Hampel H Gallacher J Hull M Rujescu D Giegling I Goate AM Kauwe JS Cruchaga C Nowotny P Morris JC Mayo K Sleegers K Bettens K Engelborghs S De Deyn PP Van Broeckhoven C Livingston G Bass NJ Gurling H McQuillin A Gwilliam R Deloukas P Al-Chalabi A Shaw CE Tsolaki M Singleton AB Guerreiro R Muhleisen TW Nothen MM Moebus S Jockel KH Klopp N Wichmann HE Pankratz VS Sando SB Aasly JO Barcikowska M Wszolek ZK Dickson DW Graff-Radford NR Petersen RC van Duijn CM Breteler MM Ikram MA DeStefano AL Fitzpatrick AL Lopez O Launer LJ Seshadri S Berr C Campion D Epelbaum J Dartigues JF Tzourio C Alperovitch A Lathrop M Feulner TM Friedrich P Riehle C Krawczak M Schreiber S Mayhaus M Nicolhaus S Wagenpfeil S Steinberg S Stefansson H Stefansson K Snaedal J Bjornsson S Jonsson PV Chouraki V Genier-Boley B Hiltunen M Soininen H Combarros O Zelenika D Delepine M Bullido MJ Pasquier F Mateo I Frank-Garcia A Porcellini E Hanon O Coto E Alvarez V Bosco P Siciliano G Mancuso M Panza F Solfrizzi V Nacmias B Sorbi S Bossu P Piccardi P Arosio B Annoni G Seripa D Pilotto A Scarpini E Galimberti D Brice A Hannequin D Licastro F Jones L Holmans PA Jonsson T Riemenschneider M Morgan K Younkin SG Owen MJ O’Donovan M Amouyel P Williams J consortium E, consortium C, Alzheimer’s Disease Neuroimaging I 2011 Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease Nature genetics 43 5 429 435 10.1038/ng.803 21460840
Hu X Pickering E Liu YC Hall S Fournier H Katz E Dechairo B John S Van Eerdewegh P Soares H Alzheimer’s Disease Neuroimaging I 2011 Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer’s disease PLoS One 6 2 e16616 10.1371/journal.pone.0016616 21390209
Jiang T Yu JT Hu N Tan MS Zhu XC Tan L 2014 CD33 in Alzheimer’s disease Molecular neurobiology 49 1 529 535 10.1007/s12035-013-8536-1 23982747
Jones L Holmans PA Hamshere ML Harold D Moskvina V Ivanov D Pocklington A Abraham R Hollingworth P Sims R Gerrish A Pahwa JS Jones N Stretton A Morgan AR Lovestone S Powell J Proitsi P Lupton MK Brayne C Rubinsztein DC Gill M Lawlor B Lynch A Morgan K Brown KS Passmore PA Craig D McGuinness B Todd S Holmes C Mann D Smith AD Love S Kehoe PG Mead S Fox N Rossor M Collinge J Maier W Jessen F Schurmann B Heun R Kolsch H van den Bussche H Heuser I Peters O Kornhuber J Wiltfang J Dichgans M Frolich L Hampel H Hull M Rujescu D Goate AM Kauwe JS Cruchaga C Nowotny P Morris JC Mayo K Livingston G Bass NJ Gurling H McQuillin A Gwilliam R Deloukas P Al-Chalabi A Shaw CE Singleton AB Guerreiro R Muhleisen TW Nothen MM Moebus S Jockel KH Klopp N Wichmann HE Ruther E Carrasquillo MM Pankratz VS Younkin SG Hardy J O’Donovan MC Owen MJ Williams J 2010 Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease PLoS One 5 11 e13950 10.1371/journal.pone.0013950 21085570
Jun G Ibrahim-Verbaas CA Vronskaya M Lambert JC Chung J Naj AC Kunkle BW Wang LS Bis JC Bellenguez C Harold D Lunetta KL Destefano AL Grenier-Boley B Sims R Beecham GW Smith AV Chouraki V Hamilton-Nelson KL Ikram MA Fievet N Denning N Martin ER Schmidt H Kamatani Y Dunstan ML Valladares O Laza AR Zelenika D Ramirez A Foroud TM Choi SH Boland A Becker T Kukull WA van der Lee SJ Pasquier F Cruchaga C Beekly D Fitzpatrick AL Hanon O Gill M Barber R Gudnason V Campion D Love S Bennett DA Amin N Berr C Tsolaki M Buxbaum JD Lopez OL Deramecourt V Fox NC Cantwell LB Tarraga L Dufouil C Hardy J Crane PK Eiriksdottir G Hannequin D Clarke R Evans D Mosley TH Jr Letenneur L Brayne C Maier W De Jager P Emilsson V Dartigues JF Hampel H Kamboh MI de Bruijn RF Tzourio C Pastor P Larson EB Rotter JI O’Donovan MC Montine TJ Nalls MA Mead S Reiman EM Jonsson PV Holmes C St George-Hyslop PH Boada M Passmore P Wendland JR Schmidt R Morgan K Winslow AR Powell JF Carasquillo M Younkin SG Jakobsdottir J Kauwe JS Wilhelmsen KC Rujescu D Nothen MM Hofman A Jones L Haines JL Psaty BM Van Broeckhoven C Holmans P Launer LJ Mayeux R Lathrop M Goate AM Escott-Price V Seshadri S Pericak-Vance MA Amouyel P Williams J van Duijn CM Schellenberg GD Farrer LA Consortium I 2016 A novel Alzheimer disease locus located near the gene encoding tau protein Mol Psychiatry 21 1 108 117 10.1038/mp.2015.23 25778476
Kajiho H Saito K Tsujita K Kontani K Araki Y Kurosu H Katada T 2003 RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway Journal of cell science 116 Pt 20 4159 4168 10.1242/jcs.00718 12972505
Kamboh MI Barmada MM Demirci FY Minster RL Carrasquillo MM Pankratz VS Younkin SG Saykin AJ Sweet RA Feingold E DeKosky ST Lopez OL Alzheimer’s Disease Neuroimaging I 2012a Genome-wide association analysis of age-at-onset in Alzheimer’s disease Mol Psychiatry 17 12 1340 1346 10.1038/mp.2011.135 22005931
Kamboh MI Demirci FY Wang X Minster RL Carrasquillo MM Pankratz VS Younkin SG Saykin AJ Jun G Baldwin C Logue MW Buros J Farrer L Pericak-Vance MA Haines JL Sweet RA Ganguli M Feingold E Dekosky ST Lopez OL Barmada MM Alzheimer’s Disease Neuroimaging I 2012b Genome-wide association study of Alzheimer’s disease Transl Psychiatry 2 e117 10.1038/tp.2012.45 22832961
Kim S Swaminathan S Shen L Risacher SL Nho K Foroud T Shaw LM Trojanowski JQ Potkin SG Huentelman MJ Craig DW DeChairo BM Aisen PS Petersen RC Weiner MW Saykin AJ Alzheimer’s Disease Neuroimaging I 2011 Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort Neurology 76 1 69 79 10.1212/WNL.0b013e318204a397 21123754
Kim TW Song IU Jeong DS Lee KS 2016 Clinical effect of cerebrovascular atherosclerosis on cognition in Alzheimer’s disease Archives of gerontology and geriatrics 63 55 58 10.1016/j.archger.2015.11.009 26631627
Lambert JC Heath S Even G Campion D Sleegers K Hiltunen M Combarros O Zelenika D Bullido MJ Tavernier B Letenneur L Bettens K Berr C Pasquier F Fievet N Barberger-Gateau P Engelborghs S De Deyn P Mateo I Franck A Helisalmi S Porcellini E Hanon O de Pancorbo MM Lendon C Dufouil C Jaillard C Leveillard T Alvarez V Bosco P Mancuso M Panza F Nacmias B Bossu P Piccardi P Annoni G Seripa D Galimberti D Hannequin D Licastro F Soininen H Ritchie K Blanche H Dartigues JF Tzourio C Gut I Van Broeckhoven C Alperovitch A Lathrop M Amouyel P European Alzheimer’s Disease Initiative I 2009 Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease Nature genetics 41 10 1094 1099 10.1038/ng.439 19734903
Lambert JC Ibrahim-Verbaas CA Harold D Naj AC Sims R Bellenguez C DeStafano AL Bis JC Beecham GW Grenier-Boley B Russo G Thorton-Wells TA Jones N Smith AV Chouraki V Thomas C Ikram MA Zelenika D Vardarajan BN Kamatani Y Lin CF Gerrish A Schmidt H Kunkle B Dunstan ML Ruiz A Bihoreau MT Choi SH Reitz C Pasquier F Cruchaga C Craig D Amin N Berr C Lopez OL De Jager PL Deramecourt V Johnston JA Evans D Lovestone S Letenneur L Moron FJ Rubinsztein DC Eiriksdottir G Sleegers K Goate AM Fievet N Huentelman MW Gill M Brown K Kamboh MI Keller L Barberger-Gateau P McGuiness B Larson EB Green R Myers AJ Dufouil C Todd S Wallon D Love S Rogaeva E Gallacher J St George-Hyslop P Clarimon J Lleo A Bayer A Tsuang DW Yu L Tsolaki M Bossu P Spalletta G Proitsi P Collinge J Sorbi S Sanchez-Garcia F Fox NC Hardy J Deniz Naranjo MC Bosco P Clarke R Brayne C Galimberti D Mancuso M Matthews F Moebus S Mecocci P Del Zompo M Maier W Hampel H Pilotto A Bullido M Panza F Caffarra P Nacmias B Gilbert JR Mayhaus M Lannefelt L Hakonarson H Pichler S Carrasquillo MM Ingelsson M Beekly D Alvarez V Zou F Valladares O Younkin SG Coto E Hamilton-Nelson KL Gu W Razquin C Pastor P Mateo I Owen MJ Faber KM Jonsson PV Combarros O O’Donovan MC Cantwell LB Soininen H Blacker D Mead S Mosley TH Jr Bennett DA Harris TB Fratiglioni L Holmes C de Bruijn RF Passmore P Montine TJ Bettens K Rotter JI Brice A Morgan K Foroud TM Kukull WA Hannequin D Powell JF Nalls MA Ritchie K Lunetta KL Kauwe JS Boerwinkle E Riemenschneider M Boada M Hiltuenen M Martin ER Schmidt R Rujescu D Wang LS Dartigues JF Mayeux R Tzourio C Hofman A Nothen MM Graff C Psaty BM Jones L Haines JL Holmans PA Lathrop M Pericak-Vance MA Launer LJ Farrer LA van Duijn CM Van Broeckhoven C Moskvina V Seshadri S Williams J Schellenberg GD Amouyel P European Alzheimer’s Disease I, Genetic, Environmental Risk in Alzheimer’s D Alzheimer’s Disease Genetic C, Cohorts for H, Aging Research in Genomic E 2013 Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease Nature genetics 45 12 1452 1458 10.1038/ng.2802 24162737
Larsson M Duffy DL Zhu G Liu JZ Macgregor S McRae AF Wright MJ Sturm RA Mackey DA Montgomery GW Martin NG Medland SE 2011 GWAS findings for human iris patterns: associations with variants in genes that influence normal neuronal pattern development American journal of human genetics 89 2 334 343 10.1016/j.ajhg.2011.07.011 21835309
Lathe R Sapronova A Kotelevtsev Y 2014 Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature BMC geriatrics 14 36 10.1186/1471-2318-14-36 24656052
Lee EJ Banerjee S Zhou H Jammalamadaka A Arcila M Manjunath BS Kosik KS 2011 Identification of piRNAs in the central nervous system RNA 17 6 1090 1099 10.1261/rna.2565011 21515829
Li H Wetten S Li L St Jean PL Upmanyu R Surh L Hosford D Barnes MR Briley JD Borrie M Coletta N Delisle R Dhalla D Ehm MG Feldman HH Fornazzari L Gauthier S Goodgame N Guzman D Hammond S Hollingworth P Hsiung GY Johnson J Kelly DD Keren R Kertesz A King KS Lovestone S Loy-English I Matthews PM Owen MJ Plumpton M Pryse-Phillips W Prinjha RK Richardson JC Saunders A Slater AJ St George-Hyslop PH Stinnett SW Swartz JE Taylor RL Wherrett J Williams J Yarnall DP Gibson RA Irizarry MC Middleton LT Roses AD 2008 Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease Arch Neurol 65 1 45 53 17998437
Li X Long J He T Belshaw R Scott J 2015 Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer’s disease Scientific reports 5 12393 10.1038/srep12393 26202100
Lilius L Froelich Fabre S Basun H Forsell C Axelman K Mattila K Andreadis A Viitanen M Winblad B Fratiglioni L Lannfelt L 1999 Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer’s disease Neuroscience letters 277 1 29 32 10643890
Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology Study G 2011 A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 68 12 1569 1579 10.1001/archneurol.2011.646 22159054
Mahley RW 2016 Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism Arteriosclerosis, thrombosis, and vascular biology 36 7 1305 1315 10.1161/ATVBAHA.116.307023
Mani SR Juliano CE 2013 Untangling the web: the diverse functions of the PIWI/piRNA pathway Mol Reprod Dev 80 8 632 664 10.1002/mrd.22195 23712694
Masters CL Simms G Weinman NA Multhaup G McDonald BL Beyreuther K 1985 Amyloid plaque core protein in Alzheimer disease and Down syndrome Proceedings of the National Academy of Sciences of the United States of America 82 12 4245 4249 3159021
Meda SA Narayanan B Liu J Perrone-Bizzozero NI Stevens MC Calhoun VD Glahn DC Shen L Risacher SL Saykin AJ Pearlson GD 2012 A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer’s disease in the ADNI cohort NeuroImage 60 3 1608 1621 10.1016/j.neuroimage.2011.12.076 22245343
Melville SA Buros J Parrado AR Vardarajan B Logue MW Shen L Risacher SL Kim S Jun G DeCarli C Lunetta KL Baldwin CT Saykin AJ Farrer LA Alzheimer’s Disease Neuroimaging I 2012 Multiple loci influencing hippocampal degeneration identified by genome scan Ann Neurol 72 1 65 75 10.1002/ana.23644 22745009
Miyashita A Koike A Jun G Wang LS Takahashi S Matsubara E Kawarabayashi T Shoji M Tomita N Arai H Asada T Harigaya Y Ikeda M Amari M Hanyu H Higuchi S Ikeuchi T Nishizawa M Suga M Kawase Y Akatsu H Kosaka K Yamamoto T Imagawa M Hamaguchi T Yamada M Morihara T Takeda M Takao T Nakata K Fujisawa Y Sasaki K Watanabe K Nakashima K Urakami K Ooya T Takahashi M Yuzuriha T Serikawa K Yoshimoto S Nakagawa R Kim JW Ki CS Won HH Na DL Seo SW Mook-Jung I St George-Hyslop P Mayeux R Haines JL Pericak-Vance MA Yoshida M Nishida N Tokunaga K Yamamoto K Tsuji S Kanazawa I Ihara Y Schellenberg GD Farrer LA Kuwano R Alzheimer Disease Genetics C 2013 SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians PLoS One 8 4 e58618 10.1371/journal.pone.0058618 23565137
Naj AC Beecham GW Martin ER Gallins PJ Powell EH Konidari I Whitehead PL Cai G Haroutunian V Scott WK Vance JM Slifer MA Gwirtsman HE Gilbert JR Haines JL Buxbaum JD Pericak-Vance MA 2010 Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities PLoS Genet 6 9 e1001130 10.1371/journal.pgen.1001130 20885792
Naj AC Jun G Beecham GW Wang LS Vardarajan BN Buros J Gallins PJ Buxbaum JD Jarvik GP Crane PK Larson EB Bird TD Boeve BF Graff-Radford NR De Jager PL Evans D Schneider JA Carrasquillo MM Ertekin-Taner N Younkin SG Cruchaga C Kauwe JS Nowotny P Kramer P Hardy J Huentelman MJ Myers AJ Barmada MM Demirci FY Baldwin CT Green RC Rogaeva E St George-Hyslop P Arnold SE Barber R Beach T Bigio EH Bowen JD Boxer A Burke JR Cairns NJ Carlson CS Carney RM Carroll SL Chui HC Clark DG Corneveaux J Cotman CW Cummings JL DeCarli C DeKosky ST Diaz-Arrastia R Dick M Dickson DW Ellis WG Faber KM Fallon KB Farlow MR Ferris S Frosch MP Galasko DR Ganguli M Gearing M Geschwind DH Ghetti B Gilbert JR Gilman S Giordani B Glass JD Growdon JH Hamilton RL Harrell LE Head E Honig LS Hulette CM Hyman BT Jicha GA Jin LW Johnson N Karlawish J Karydas A Kaye JA Kim R Koo EH Kowall NW Lah JJ Levey AI Lieberman AP Lopez OL Mack WJ Marson DC Martiniuk F Mash DC Masliah E McCormick WC McCurry SM McDavid AN McKee AC Mesulam M Miller BL Miller CA Miller JW Parisi JE Perl DP Peskind E Petersen RC Poon WW Quinn JF Rajbhandary RA Raskind M Reisberg B Ringman JM Roberson ED Rosenberg RN Sano M Schneider LS Seeley W Shelanski ML Slifer MA Smith CD Sonnen JA Spina S Stern RA Tanzi RE Trojanowski JQ Troncoso JC Van Deerlin VM Vinters HV Vonsattel JP Weintraub S Welsh-Bohmer KA Williamson J Woltjer RL Cantwell LB Dombroski BA Beekly D Lunetta KL Martin ER Kamboh MI Saykin AJ Reiman EM Bennett DA Morris JC Montine TJ Goate AM Blacker D Tsuang DW Hakonarson H Kukull WA Foroud TM Haines JL Mayeux R Pericak-Vance MA Farrer LA Schellenberg GD 2011 Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease Nature genetics 43 5 436 441 10.1038/ng.801 21460841
Namba Y Tomonaga M Kawasaki H Otomo E Ikeda K 1991 Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease Brain research 541 1 163 166 2029618
Nelson PT Estus S Abner EL Parikh I Malik M Neltner JH Ighodaro E Wang WX Wilfred BR Wang LS Kukull WA Nandakumar K Farman ML Poon WW Corrada MM Kawas CH Cribbs DH Bennett DA Schneider JA Larson EB Crane PK Valladares O Schmitt FA Kryscio RJ Jicha GA Smith CD Scheff SW Sonnen JA Haines JL Pericak-Vance MA Mayeux R Farrer LA Van Eldik LJ Horbinski C Green RC Gearing M Poon LW Kramer PL Woltjer RL Montine TJ Partch AB Rajic AJ Richmire K Monsell SE Schellenberg GD Fardo DW Alzheimer’ Disease Genetic C 2014 ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology Acta Neuropathol 127 6 825 843 10.1007/s00401-014-1282-2 24770881
Peng JC Lin H 2013 Beyond transposons: the epigenetic and somatic functions of the Piwi-piRNA mechanism Curr Opin Cell Biol 25 2 190 194 10.1016/j.ceb.2013.01.010 23465540
Perez-Palma E Bustos BI Villaman CF Alarcon MA Avila ME Ugarte GD Reyes AE Opazo C De Ferrari GV Alzheimer’s Disease Neuroimaging I, Group N-LNFS 2014 Overrepresentation of glutamate signaling in Alzheimer’s disease: network-based pathway enrichment using meta-analysis of genome-wide association studies PLoS One 9 4 e95413 10.1371/journal.pone.0095413 24755620
Perrat PN DasGupta S Wang J Theurkauf W Weng Z Rosbash M Waddell S 2013 Transposition-driven genomic heterogeneity in the Drosophila brain Science 340 6128 91 95 10.1126/science.1231965 23559253
Puglielli L Tanzi RE Kovacs DM 2003 Alzheimer’s disease: the cholesterol connection Nature neuroscience 6 4 345 351 10.1038/nn0403-345 12658281
Qiu W Guo X Lin X Yang Q Zhang W Zhang Y Zuo L Zhu Y Li CR Ma C Luo X 2017 Transcriptome-wide piRNA profiling in human brains of Alzheimer’s disease Neurobiology of aging 57 170 177 10.1016/j.neurobiolaging.2017.05.020 28654860
Rajasethupathy P Antonov I Sheridan R Frey S Sander C Tuschl T Kandel ER 2012 A role for neuronal piRNAs in the epigenetic control of memory-related synaptic plasticity Cell 149 3 693 707 10.1016/j.cell.2012.02.057 22541438
Ramanan VK Risacher SL Nho K Kim S Swaminathan S Shen L Foroud TM Hakonarson H Huentelman MJ Aisen PS Petersen RC Green RC Jack CR Koeppe RA Jagust WJ Weiner MW Saykin AJ Alzheimer’s Disease Neuroimaging I 2014 APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study Mol Psychiatry 19 3 351 357 10.1038/mp.2013.19 23419831
Ramirez A van der Flier WM Herold C Ramonet D Heilmann S Lewczuk P Popp J Lacour A Drichel D Louwersheimer E Kummer MP Cruchaga C Hoffmann P Teunissen C Holstege H Kornhuber J Peters O Naj AC Chouraki V Bellenguez C Gerrish A Heun R Frolich L Hull M Buscemi L Herms S Kolsch H Scheltens P Breteler MM Ruther E Wiltfang J Goate A Jessen F Maier W Heneka MT Becker T Nothen MM International Genomics of Alzheimer’s P, Alzheimer’s Disease Neuroimaging I 2014 SUCLG2 identified as both a determinator of CSF Abeta1-42 levels and an attenuator of cognitive decline in Alzheimer’s disease Hum Mol Genet 23 24 6644 6658 10.1093/hmg/ddu372 25027320
Ross RJ Weiner MM Lin H 2014 PIWI proteins and PIWI-interacting RNAs in the soma Nature 505 7483 353 359 10.1038/nature12987 24429634
Sandoval-Hernandez AG Buitrago L Moreno H Cardona-Gomez GP Arboleda G 2015 Role of Liver X Receptor in AD Pathophysiology PLoS One 10 12 e0145467 10.1371/journal.pone.0145467 26720273
Seshadri S Fitzpatrick AL Ikram MA DeStefano AL Gudnason V Boada M Bis JC Smith AV Carassquillo MM Lambert JC Harold D Schrijvers EM Ramirez-Lorca R Debette S Longstreth WT Jr Janssens AC Pankratz VS Dartigues JF Hollingworth P Aspelund T Hernandez I Beiser A Kuller LH Koudstaal PJ Dickson DW Tzourio C Abraham R Antunez C Du Y Rotter JI Aulchenko YS Harris TB Petersen RC Berr C Owen MJ Lopez-Arrieta J Varadarajan BN Becker JT Rivadeneira F Nalls MA Graff-Radford NR Campion D Auerbach S Rice K Hofman A Jonsson PV Schmidt H Lathrop M Mosley TH Au R Psaty BM Uitterlinden AG Farrer LA Lumley T Ruiz A Williams J Amouyel P Younkin SG Wolf PA Launer LJ Lopez OL van Duijn CM Breteler MM Consortium C, Consortium G, Consortium E 2010 Genome-wide analysis of genetic loci associated with Alzheimer disease JAMA 303 18 1832 1840 10.1001/jama.2010.574 20460622
Sharma AK Nelson MC Brandt JE Wessman M Mahmud N Weller KP Hoffman R 2001 Human CD34(+) stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi Blood 97 2 426 434 11154219
Shen L Kim S Risacher SL Nho K Swaminathan S West JD Foroud T Pankratz N Moore JH Sloan CD Huentelman MJ Craig DW Dechairo BM Potkin SG Jack CR Jr Weiner MW Saykin AJ Alzheimer’s Disease Neuroimaging I 2010 Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort NeuroImage 53 3 1051 1063 10.1016/j.neuroimage.2010.01.042 20100581
Tan MS Yu JT Tan L 2013 Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease Trends in molecular medicine 19 10 594 603 10.1016/j.molmed.2013.06.004 23871436
Thambisetty M An Y Nalls M Sojkova J Swaminathan S Zhou Y Singleton AB Wong DF Ferrucci L Saykin AJ Resnick SM Baltimore Longitudinal Study of A, the Alzheimer’s Disease Neuroimaging I 2013 Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype Biological psychiatry 73 5 422 428 10.1016/j.biopsych.2012.08.015 23022416
Treusch S Hamamichi S Goodman JL Matlack KE Chung CY Baru V Shulman JM Parrado A Bevis BJ Valastyan JS Han H Lindhagen-Persson M Reiman EM Evans DA Bennett DA Olofsson A DeJager PL Tanzi RE Caldwell KA Caldwell GA Lindquist S 2011 Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer’s disease risk factors in yeast Science 334 6060 1241 1245 10.1126/science.1213210 22033521
Villegas VE Zaphiropoulos PG 2015 Neighboring gene regulation by antisense long non-coding RNAs International journal of molecular sciences 16 2 3251 3266 10.3390/ijms16023251 25654223
Wang Z Lei H Zheng M Li Y Cui Y Hao F 2016 Meta-analysis of the Association between Alzheimer Disease and Variants in GAB2, PICALM, and SORL1 Molecular neurobiology 53 9 6501 6510 10.1007/s12035-015-9546-y 26611835
Webster JA Myers AJ Pearson JV Craig DW Hu-Lince D Coon KD Zismann VL Beach T Leung D Bryden L Halperin RF Marlowe L Kaleem M Huentelman MJ Joshipura K Walker D Heward CB Ravid R Rogers J Papassotiropoulos A Hardy J Reiman EM Stephan DA 2008 Sorl1 as an Alzheimer’s disease predisposition gene? Neurodegener Dis 5 2 60 64 10.1159/000110789 17975299
Xiao Q Gil SC Yan P Wang Y Han S Gonzales E Perez R Cirrito JR Lee JM 2012 Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis The Journal of biological chemistry 287 25 21279 21289 10.1074/jbc.M111.338376 22539346
Yan Z Hu HY Jiang X Maierhofer V Neb E He L Hu Y Hu H Li N Chen W Khaitovich P 2011 Widespread expression of piRNA-like molecules in somatic tissues Nucleic acids research 39 15 6596 6607 10.1093/nar/gkr298 21546553
Zuo L Tan Y Wang Z Wang K Zhang X Chen X Li C Wang T Luo X 2016a Long non-coding RNAs in psychiatric disorders Psychiatric Genet 26 3 109 116
Zuo L Wang Z Tan Y Chen X Luo X 2016b piRNAs and their functions in the brain Int J Hum Genet 16 1–2 53 60 27512315
References

1 Lambert JC Ibrahim-Verbaas CA Harold D Naj AC Sims R Bellenguez C DeStafano AL Bis JC Beecham GW Grenier-Boley B Russo G Thorton-Wells TA Jones N Smith AV Chouraki V Thomas C Ikram MA Zelenika D Vardarajan BN Kamatani Y Lin CF Gerrish A Schmidt H Kunkle B Dunstan ML Ruiz A Bihoreau MT Choi SH Reitz C Pasquier F Cruchaga C Craig D Amin N Berr C Lopez OL De Jager PL Deramecourt V Johnston JA Evans D Lovestone S Letenneur L Moron FJ Rubinsztein DC Eiriksdottir G Sleegers K Goate AM Fievet N Huentelman MW Gill M Brown K Kamboh MI Keller L Barberger-Gateau P McGuiness B Larson EB Green R Myers AJ Dufouil C Todd S Wallon D Love S Rogaeva E Gallacher J St George-Hyslop P Clarimon J Lleo A Bayer A Tsuang DW Yu L Tsolaki M Bossu P Spalletta G Proitsi P Collinge J Sorbi S Sanchez-Garcia F Fox NC Hardy J Deniz Naranjo MC Bosco P Clarke R Brayne C Galimberti D Mancuso M Matthews F Moebus S Mecocci P Del Zompo M Maier W Hampel H Pilotto A Bullido M Panza F Caffarra P Nacmias B Gilbert JR Mayhaus M Lannefelt L Hakonarson H Pichler S Carrasquillo MM Ingelsson M Beekly D Alvarez V Zou F Valladares O Younkin SG Coto E Hamilton-Nelson KL Gu W Razquin C Pastor P Mateo I Owen MJ Faber KM Jonsson PV Combarros O O’Donovan MC Cantwell LB Soininen H Blacker D Mead S Mosley TH Jr Bennett DA Harris TB Fratiglioni L Holmes C de Bruijn RF Passmore P Montine TJ Bettens K Rotter JI Brice A Morgan K Foroud TM Kukull WA Hannequin D Powell JF Nalls MA Ritchie K Lunetta KL Kauwe JS Boerwinkle E Riemenschneider M Boada M Hiltuenen M Martin ER Schmidt R Rujescu D Wang LS Dartigues JF Mayeux R Tzourio C Hofman A Nothen MM Graff C Psaty BM Jones L Haines JL Holmans PA Lathrop M Pericak-Vance MA Launer LJ Farrer LA van Duijn CM Van Broeckhoven C Moskvina V Seshadri S Williams J Schellenberg GD Amouyel P European Alzheimer’s Disease I, Genetic, Environmental Risk in Alzheimer’s D, Alzheimer’s Disease Genetic C, Cohorts for H, Aging Research in Genomic E 2013 Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease Nat Genet 45 1452 1458 24162737
2 Lambert JC Heath S Even G Campion D Sleegers K Hiltunen M Combarros O Zelenika D Bullido MJ Tavernier B Letenneur L Bettens K Berr C Pasquier F Fievet N Barberger-Gateau P Engelborghs S De Deyn P Mateo I Franck A Helisalmi S Porcellini E Hanon O de Pancorbo MM Lendon C Dufouil C Jaillard C Leveillard T Alvarez V Bosco P Mancuso M Panza F Nacmias B Bossu P Piccardi P Annoni G Seripa D Galimberti D Hannequin D Licastro F Soininen H Ritchie K Blanche H Dartigues JF Tzourio C Gut I Van Broeckhoven C Alperovitch A Lathrop M Amouyel P European Alzheimer’s Disease Initiative I 2009 Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease Nat Genet 41 1094 1099 19734903
3 Kamboh MI Demirci FY Wang X Minster RL Carrasquillo MM Pankratz VS Younkin SG Saykin AJ Jun G Baldwin C Logue MW Buros J Farrer L Pericak-Vance MA Haines JL Sweet RA Ganguli M Feingold E Dekosky ST Lopez OL Barmada MM Alzheimer’s Disease Neuroimaging I 2012 Genome-wide association study of Alzheimer’s disease Transl Psychiatry 2 e117 22832961
4 Naj AC Jun G Beecham GW Wang LS Vardarajan BN Buros J Gallins PJ Buxbaum JD Jarvik GP Crane PK Larson EB Bird TD Boeve BF Graff-Radford NR De Jager PL Evans D Schneider JA Carrasquillo MM Ertekin-Taner N Younkin SG Cruchaga C Kauwe JS Nowotny P Kramer P Hardy J Huentelman MJ Myers AJ Barmada MM Demirci FY Baldwin CT Green RC Rogaeva E St George-Hyslop P Arnold SE Barber R Beach T Bigio EH Bowen JD Boxer A Burke JR Cairns NJ Carlson CS Carney RM Carroll SL Chui HC Clark DG Corneveaux J Cotman CW Cummings JL DeCarli C DeKosky ST Diaz-Arrastia R Dick M Dickson DW Ellis WG Faber KM Fallon KB Farlow MR Ferris S Frosch MP Galasko DR Ganguli M Gearing M Geschwind DH Ghetti B Gilbert JR Gilman S Giordani B Glass JD Growdon JH Hamilton RL Harrell LE Head E Honig LS Hulette CM Hyman BT Jicha GA Jin LW Johnson N Karlawish J Karydas A Kaye JA Kim R Koo EH Kowall NW Lah JJ Levey AI Lieberman AP Lopez OL Mack WJ Marson DC Martiniuk F Mash DC Masliah E McCormick WC McCurry SM McDavid AN McKee AC Mesulam M Miller BL Miller CA Miller JW Parisi JE Perl DP Peskind E Petersen RC Poon WW Quinn JF Rajbhandary RA Raskind M Reisberg B Ringman JM Roberson ED Rosenberg RN Sano M Schneider LS Seeley W Shelanski ML Slifer MA Smith CD Sonnen JA Spina S Stern RA Tanzi RE Trojanowski JQ Troncoso JC Van Deerlin VM Vinters HV Vonsattel JP Weintraub S Welsh-Bohmer KA Williamson J Woltjer RL Cantwell LB Dombroski BA Beekly D Lunetta KL Martin ER Kamboh MI Saykin AJ Reiman EM Bennett DA Morris JC Montine TJ Goate AM Blacker D Tsuang DW Hakonarson H Kukull WA Foroud TM Haines JL Mayeux R Pericak-Vance MA Farrer LA Schellenberg GD 2011 Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease Nat Genet 43 436 441 21460841
5 Jun G Ibrahim-Verbaas CA Vronskaya M Lambert JC Chung J Naj AC Kunkle BW Wang LS Bis JC Bellenguez C Harold D Lunetta KL Destefano AL Grenier-Boley B Sims R Beecham GW Smith AV Chouraki V Hamilton-Nelson KL Ikram MA Fievet N Denning N Martin ER Schmidt H Kamatani Y Dunstan ML Valladares O Laza AR Zelenika D Ramirez A Foroud TM Choi SH Boland A Becker T Kukull WA van der Lee SJ Pasquier F Cruchaga C Beekly D Fitzpatrick AL Hanon O Gill M Barber R Gudnason V Campion D Love S Bennett DA Amin N Berr C Tsolaki M Buxbaum JD Lopez OL Deramecourt V Fox NC Cantwell LB Tarraga L Dufouil C Hardy J Crane PK Eiriksdottir G Hannequin D Clarke R Evans D Mosley TH Jr Letenneur L Brayne C Maier W De Jager P Emilsson V Dartigues JF Hampel H Kamboh MI de Bruijn RF Tzourio C Pastor P Larson EB Rotter JI O’Donovan MC Montine TJ Nalls MA Mead S Reiman EM Jonsson PV Holmes C St George-Hyslop PH Boada M Passmore P Wendland JR Schmidt R Morgan K Winslow AR Powell JF Carasquillo M Younkin SG Jakobsdottir J Kauwe JS Wilhelmsen KC Rujescu D Nothen MM Hofman A Jones L Haines JL Psaty BM Van Broeckhoven C Holmans P Launer LJ Mayeux R Lathrop M Goate AM Escott-Price V Seshadri S Pericak-Vance MA Amouyel P Williams J van Duijn CM Schellenberg GD Farrer LA Consortium I 2016 A novel Alzheimer disease locus located near the gene encoding tau protein Mol Psychiatry 21 108 117 25778476
6 Hollingworth P Harold D Sims R Gerrish A Lambert JC Carrasquillo MM Abraham R Hamshere ML Pahwa JS Moskvina V Dowzell K Jones N Stretton A Thomas C Richards A Ivanov D Widdowson C Chapman J Lovestone S Powell J Proitsi P Lupton MK Brayne C Rubinsztein DC Gill M Lawlor B Lynch A Brown KS Passmore PA Craig D McGuinness B Todd S Holmes C Mann D Smith AD Beaumont H Warden D Wilcock G Love S Kehoe PG Hooper NM Vardy ER Hardy J Mead S Fox NC Rossor M Collinge J Maier W Jessen F Ruther E Schurmann B Heun R Kolsch H van den Bussche H Heuser I Kornhuber J Wiltfang J Dichgans M Frolich L Hampel H Gallacher J Hull M Rujescu D Giegling I Goate AM Kauwe JS Cruchaga C Nowotny P Morris JC Mayo K Sleegers K Bettens K Engelborghs S De Deyn PP Van Broeckhoven C Livingston G Bass NJ Gurling H McQuillin A Gwilliam R Deloukas P Al-Chalabi A Shaw CE Tsolaki M Singleton AB Guerreiro R Muhleisen TW Nothen MM Moebus S Jockel KH Klopp N Wichmann HE Pankratz VS Sando SB Aasly JO Barcikowska M Wszolek ZK Dickson DW Graff-Radford NR Petersen RC van Duijn CM Breteler MM Ikram MA DeStefano AL Fitzpatrick AL Lopez O Launer LJ Seshadri S Berr C Campion D Epelbaum J Dartigues JF Tzourio C Alperovitch A Lathrop M Feulner TM Friedrich P Riehle C Krawczak M Schreiber S Mayhaus M Nicolhaus S Wagenpfeil S Steinberg S Stefansson H Stefansson K Snaedal J Bjornsson S Jonsson PV Chouraki V Genier-Boley B Hiltunen M Soininen H Combarros O Zelenika D Delepine M Bullido MJ Pasquier F Mateo I Frank-Garcia A Porcellini E Hanon O Coto E Alvarez V Bosco P Siciliano G Mancuso M Panza F Solfrizzi V Nacmias B Sorbi S Bossu P Piccardi P Arosio B Annoni G Seripa D Pilotto A Scarpini E Galimberti D Brice A Hannequin D Licastro F Jones L Holmans PA Jonsson T Riemenschneider M Morgan K Younkin SG Owen MJ O’Donovan M Amouyel P Williams J consortium E, consortium C, Alzheimer’s Disease Neuroimaging I 2011 Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease Nat Genet 43 429 435 21460840
7 Antunez C Boada M Gonzalez-Perez A Gayan J Ramirez-Lorca R Marin J Hernandez I Moreno-Rey C Moron FJ Lopez-Arrieta J Mauleon A Rosende-Roca M Noguera-Perea F Legaz-Garcia A Vivancos-Moreau L Velasco J Carrasco JM Alegret M Antequera-Torres M Manzanares S Romo A Blanca I Ruiz S Espinosa A Castano S Garcia B Martinez-Herrada B Vinyes G Lafuente A Becker JT Galan JJ Serrano-Rios M Vazquez E Tarraga L Saez ME Lopez OL Real LM Ruiz A Alzheimer’s Disease Neuroimaging I 2011 The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease Genome Med 3 33 21627779
8 Hu X Pickering E Liu YC Hall S Fournier H Katz E Dechairo B John S Van Eerdewegh P Soares H Alzheimer’s Disease Neuroimaging I 2011 Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer’s disease PLoS One 6 e16616 21390209
9 Miyashita A Koike A Jun G Wang LS Takahashi S Matsubara E Kawarabayashi T Shoji M Tomita N Arai H Asada T Harigaya Y Ikeda M Amari M Hanyu H Higuchi S Ikeuchi T Nishizawa M Suga M Kawase Y Akatsu H Kosaka K Yamamoto T Imagawa M Hamaguchi T Yamada M Morihara T Takeda M Takao T Nakata K Fujisawa Y Sasaki K Watanabe K Nakashima K Urakami K Ooya T Takahashi M Yuzuriha T Serikawa K Yoshimoto S Nakagawa R Kim JW Ki CS Won HH Na DL Seo SW Mook-Jung I St George-Hyslop P Mayeux R Haines JL Pericak-Vance MA Yoshida M Nishida N Tokunaga K Yamamoto K Tsuji S Kanazawa I Ihara Y Schellenberg GD Farrer LA Kuwano R Alzheimer Disease Genetics C 2013 SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians PLoS One 8 e58618 23565137
10 Harold D Abraham R Hollingworth P Sims R Gerrish A Hamshere ML Pahwa JS Moskvina V Dowzell K Williams A Jones N Thomas C Stretton A Morgan AR Lovestone S Powell J Proitsi P Lupton MK Brayne C Rubinsztein DC Gill M Lawlor B Lynch A Morgan K Brown KS Passmore PA Craig D McGuinness B Todd S Holmes C Mann D Smith AD Love S Kehoe PG Hardy J Mead S Fox N Rossor M Collinge J Maier W Jessen F Schurmann B van den Bussche H Heuser I Kornhuber J Wiltfang J Dichgans M Frolich L Hampel H Hull M Rujescu D Goate AM Kauwe JS Cruchaga C Nowotny P Morris JC Mayo K Sleegers K Bettens K Engelborghs S De Deyn PP Van Broeckhoven C Livingston G Bass NJ Gurling H McQuillin A Gwilliam R Deloukas P Al-Chalabi A Shaw CE Tsolaki M Singleton AB Guerreiro R Muhleisen TW Nothen MM Moebus S Jockel KH Klopp N Wichmann HE Carrasquillo MM Pankratz VS Younkin SG Holmans PA O’Donovan M Owen MJ Williams J 2009 Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease Nat Genet 41 1088 1093 19734902
11 Abraham R Moskvina V Sims R Hollingworth P Morgan A Georgieva L Dowzell K Cichon S Hillmer AM O’Donovan MC Williams J Owen MJ Kirov G 2008 A genome-wide association study for late-onset Alzheimer’s disease using DNA pooling BMC Med Genomics 1 44 18823527
12 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology Study G 2011 A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 68 1569 1579 22159054
13 Naj AC Beecham GW Martin ER Gallins PJ Powell EH Konidari I Whitehead PL Cai G Haroutunian V Scott WK Vance JM Slifer MA Gwirtsman HE Gilbert JR Haines JL Buxbaum JD Pericak-Vance MA 2010 Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities PLoS Genet 6 e1001130 20885792
14 Feulner TM Laws SM Friedrich P Wagenpfeil S Wurst SH Riehle C Kuhn KA Krawczak M Schreiber S Nikolaus S Forstl H Kurz A Riemenschneider M 2010 Examination of the current top candidate genes for AD in a genome-wide association study Mol Psychiatry 15 756 766 19125160
15 Kim S Swaminathan S Shen L Risacher SL Nho K Foroud T Shaw LM Trojanowski JQ Potkin SG Huentelman MJ Craig DW DeChairo BM Aisen PS Petersen RC Weiner MW Saykin AJ Alzheimer’s Disease Neuroimaging I 2011 Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort Neurology 76 69 79 21123754
16 Nelson PT Estus S Abner EL Parikh I Malik M Neltner JH Ighodaro E Wang WX Wilfred BR Wang LS Kukull WA Nandakumar K Farman ML Poon WW Corrada MM Kawas CH Cribbs DH Bennett DA Schneider JA Larson EB Crane PK Valladares O Schmitt FA Kryscio RJ Jicha GA Smith CD Scheff SW Sonnen JA Haines JL Pericak-Vance MA Mayeux R Farrer LA Van Eldik LJ Horbinski C Green RC Gearing M Poon LW Kramer PL Woltjer RL Montine TJ Partch AB Rajic AJ Richmire K Monsell SE Schellenberg GD Fardo DW Alzheimer’ Disease Genetic C 2014 ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology Acta Neuropathol 127 825 843 24770881
17 Heinzen EL Need AC Hayden KM Chiba-Falek O Roses AD Strittmatter WJ Burke JR Hulette CM Welsh-Bohmer KA Goldstein DB 2010 Genome-wide scan of copy number variation in late-onset Alzheimer’s disease J Alzheimers Dis 19 69 77 20061627
18 Seshadri S Fitzpatrick AL Ikram MA DeStefano AL Gudnason V Boada M Bis JC Smith AV Carassquillo MM Lambert JC Harold D Schrijvers EM Ramirez-Lorca R Debette S Longstreth WT Jr Janssens AC Pankratz VS Dartigues JF Hollingworth P Aspelund T Hernandez I Beiser A Kuller LH Koudstaal PJ Dickson DW Tzourio C Abraham R Antunez C Du Y Rotter JI Aulchenko YS Harris TB Petersen RC Berr C Owen MJ Lopez-Arrieta J Varadarajan BN Becker JT Rivadeneira F Nalls MA Graff-Radford NR Campion D Auerbach S Rice K Hofman A Jonsson PV Schmidt H Lathrop M Mosley TH Au R Psaty BM Uitterlinden AG Farrer LA Lumley T Ruiz A Williams J Amouyel P Younkin SG Wolf PA Launer LJ Lopez OL van Duijn CM Breteler MM Consortium C, Consortium G, Consortium E 2010 Genome-wide analysis of genetic loci associated with Alzheimer disease JAMA 303 1832 1840 20460622
19 Perez-Palma E Bustos BI Villaman CF Alarcon MA Avila ME Ugarte GD Reyes AE Opazo C De Ferrari GV Alzheimer’s Disease Neuroimaging I, Group N-LNFS 2014 Overrepresentation of glutamate signaling in Alzheimer’s disease: network-based pathway enrichment using meta-analysis of genome-wide association studies PLoS One 9 e95413 24755620
20 Shen L Kim S Risacher SL Nho K Swaminathan S West JD Foroud T Pankratz N Moore JH Sloan CD Huentelman MJ Craig DW Dechairo BM Potkin SG Jack CR Jr Weiner MW Saykin AJ Alzheimer’s Disease Neuroimaging I 2010 Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort Neuroimage 53 1051 1063 20100581
21 Meda SA Narayanan B Liu J Perrone-Bizzozero NI Stevens MC Calhoun VD Glahn DC Shen L Risacher SL Saykin AJ Pearlson GD 2012 A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer’s disease in the ADNI cohort Neuroimage 60 1608 1621 22245343
22 Ramirez A van der Flier WM Herold C Ramonet D Heilmann S Lewczuk P Popp J Lacour A Drichel D Louwersheimer E Kummer MP Cruchaga C Hoffmann P Teunissen C Holstege H Kornhuber J Peters O Naj AC Chouraki V Bellenguez C Gerrish A Heun R Frolich L Hull M Buscemi L Herms S Kolsch H Scheltens P Breteler MM Ruther E Wiltfang J Goate A Jessen F Maier W Heneka MT Becker T Nothen MM International Genomics of Alzheimer’s P, Alzheimer’s Disease Neuroimaging I 2014 SUCLG2 identified as both a determinator of CSF Abeta1–42 levels and an attenuator of cognitive decline in Alzheimer’s disease Hum Mol Genet 23 6644 6658 25027320
23 Ramanan VK Risacher SL Nho K Kim S Swaminathan S Shen L Foroud TM Hakonarson H Huentelman MJ Aisen PS Petersen RC Green RC Jack CR Koeppe RA Jagust WJ Weiner MW Saykin AJ Alzheimer’s Disease Neuroimaging I 2014 APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study Mol Psychiatry 19 351 357 23419831
24 Melville SA Buros J Parrado AR Vardarajan B Logue MW Shen L Risacher SL Kim S Jun G DeCarli C Lunetta KL Baldwin CT Saykin AJ Farrer LA Alzheimer’s Disease Neuroimaging I 2012 Multiple loci influencing hippocampal degeneration identified by genome scan Ann Neurol 72 65 75 22745009
25 Li H Wetten S Li L St Jean PL Upmanyu R Surh L Hosford D Barnes MR Briley JD Borrie M Coletta N Delisle R Dhalla D Ehm MG Feldman HH Fornazzari L Gauthier S Goodgame N Guzman D Hammond S Hollingworth P Hsiung GY Johnson J Kelly DD Keren R Kertesz A King KS Lovestone S Loy-English I Matthews PM Owen MJ Plumpton M Pryse-Phillips W Prinjha RK Richardson JC Saunders A Slater AJ St George-Hyslop PH Stinnett SW Swartz JE Taylor RL Wherrett J Williams J Yarnall DP Gibson RA Irizarry MC Middleton LT Roses AD 2008 Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease Arch Neurol 65 45 53 17998437
26 Webster JA Myers AJ Pearson JV Craig DW Hu-Lince D Coon KD Zismann VL Beach T Leung D Bryden L Halperin RF Marlowe L Kaleem M Huentelman MJ Joshipura K Walker D Heward CB Ravid R Rogers J Papassotiropoulos A Hardy J Reiman EM Stephan DA 2008 Sorl1 as an Alzheimer’s disease predisposition gene? Neurodegener Dis 5 60 64 17975299
27 Coon KD Myers AJ Craig DW Webster JA Pearson JV Lince DH Zismann VL Beach TG Leung D Bryden L Halperin RF Marlowe L Kaleem M Walker DG Ravid R Heward CB Rogers J Papassotiropoulos A Reiman EM Hardy J Stephan DA 2007 A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease J Clin Psychiatry 68 613 618 17474819
28 Kamboh MI Barmada MM Demirci FY Minster RL Carrasquillo MM Pankratz VS Younkin SG Saykin AJ Sweet RA Feingold E DeKosky ST Lopez OL Alzheimer’s Disease Neuroimaging I 2012 Genome-wide association analysis of age-at-onset in Alzheimer’s disease Mol Psychiatry 17 1340 1346 22005931
